Clinical Trials Logo

Clinical Trial Details — Status: Recruiting

Administrative data

NCT number NCT05622318
Other study ID # PRO00046962
Secondary ID
Status Recruiting
Phase Phase 2
First received
Last updated
Start date August 29, 2023
Est. completion date December 15, 2025

Study information

Verified date August 2023
Source Medical College of Wisconsin
Contact Medical College of Wisconsin Cancer Center Clinical Trials Offic
Phone 866-680-0505
Email cccto@mcw.edu
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

This is an open-label phase 2 study designed to explore the efficacy and safety of low-dose PTCy-ruxolitinib GVHD prophylaxis in older adults undergoing allogeneic HCT with a matched sibling or unrelated donor with a peripheral blood stem cell graft.


Description:

Following reduced intensity conditioning and 8/8-matched peripheral blood transplant on Day 0, all patients will receive a GVHD prophylaxis post-transplant composed of the following: (i) cyclophosphamide administered at 25 mg/kg on Day +3 and +4, (ii) tacrolimus beginning on Day +5 and through Day +180 and administered with a trough target of 5-10 ng/ml through Day +90 and tapered thereafter; (iii) mycophenolate mofetil (MMF) administered at 15 mg/kg thrice daily beginning on Day +5 through Day +35; and (iv) ruxolitinib administered at 5 mg twice daily starting after engraftment (between Days +30 and +60) and continuing through one year post transplant.


Recruitment information / eligibility

Status Recruiting
Enrollment 56
Est. completion date December 15, 2025
Est. primary completion date December 15, 2025
Accepts healthy volunteers No
Gender All
Age group 60 Years and older
Eligibility Inclusion Criteria: 1. History of hematologic malignancy. 2. Must be in remission: - Acute Leukemia, chronic leukemia, or myelodysplasia/myeloproliferative neoplasm (excluding primary myelofibrosis): No circulating blasts and <5% blasts in the bone marrow. - Hodgkin and non-Hodgkin lymphomas: Chemo-sensitive disease at time of transplant 3. Patients must have a related or unrelated peripheral blood stem cell donor that is an 8/8 match at HLA-A, -B, -C and -DRB1 at high resolution using DNA-based typing. Unrelated donors must be willing to donate peripheral blood stem cells and meet NMDP criteria for donation. 4. Planned reduced intensity conditioning therapy with fludarabine/melphalan, with total dose of melphalan of 100-140 mg/m^2 IV or fludarabine/busulfan with total dose of busulfan of 6.4 mg/kg IV. 5. Karnofsky Performance Scale of 60 or greater. 6. Male participants must agree to abstinence or to use of barrier contraception during the entire study period. 7. Female participants of childbearing potential will require a negative pregnancy test and should agree to practice two effective methods of contraception during the entire study period. 8. Ability to understand a written informed consent document, and the willingness to sign it. Exclusion Criteria: 1. Prior allogeneic HCT or Chimeric antigen receptor (CAR) -T cell therapy. 2. Patients with liver dysfunction evidenced by bilirubin =2x upper limit normal (ULN), except for a history of Gilbert syndrome. 3. Patients with renal impairment defined by creatinine<2mg/dL. 4. Patients with cardiac dysfunction defined by a left ventricular ejection fraction =45%. 5. Patients with pulmonary dysfunction defined by a forced expiratory volume in the first second (FEV1) or diffusing capacity for carbon monoxide (DLCO) (corrected for hemoglobin) =50% of predicted. 6. Patients with a chronic or active infection requiring systemic treatment during and after transplant. 7. Presence of other active malignant disease diagnosed within 12 months, except for adequately treated non-melanoma skin cancer, adequately treated melanoma grade 2 or less, or cervical intraepithelial neoplasia. Active malignancy is malignancy receiving treatment. 8. Pregnant or lactating subjects.

Study Design


Related Conditions & MeSH terms


Intervention

Drug:
Cyclophosphamide
25 mg/kg by IV on Days +3 and +4.
Tacrolimus
Target level 5-10 ng/mL (If the subject experiences nausea and vomiting that prevents the oral intake of tacrolimus anytime during treatment, tacrolimus is to be given by IV at the appropriate dose that was used to obtain the therapeutic level [IV:PO ratio = 1:4]). Administered Days +5 through +90. Taper after Day +90 and discontinue on Day +180.
Mycophenolate Mofetil
15 mg/kg tablet thrice daily Days +5 through +35 every eight hours.
Ruxolitinib
5 mg tablet twice daily after engraftment through Day +365. Taper after Day +365.

Locations

Country Name City State
United States Froedtert Hospital & the Medical College of Wisconsin Milwaukee Wisconsin

Sponsors (1)

Lead Sponsor Collaborator
Medical College of Wisconsin

Country where clinical trial is conducted

United States, 

Outcome

Type Measure Description Time frame Safety issue
Primary The number of subjects who experience GVHD-free survival. This measure is defined as being alive without having experienced grade III/IV acute GVHD, or chronic GVHD requiring systemic immune suppression. One year (365 Days) after hematopoietic cell transplantation (HCT)
Secondary The number of subjects with acute GVHD at Day +100. The staging and grading of acute GVHD will be done according to Consensus GVHD grading criteria. Day +100 after HCT
Secondary The number of subjects with acute GVHD at Day +180. The staging and grading of acute GVHD will be done according to Consensus GVHD grading criteria. Day +180 after HCT
Secondary The number of subjects with chronic GVHD at one year. Chronic GVHD will be graded as mild, moderate, or severe according to the NIH consensus criteria. One year after HCT
Secondary The number of subjects with non-relapse mortality at Day +100. This is defined as death before day +100 after transplant that was not preceded by recurrent or progressive malignancy. Day +100 after HCT
Secondary The number of subjects with non-relapse mortality at one year. This is defined as death before day +100 after transplant that was not preceded by recurrent or progressive malignancy. One year after HCT
Secondary Overall survival at one year. This is defined as the number of subjects alive one year after HCT. One year after HCT
See also
  Status Clinical Trial Phase
Active, not recruiting NCT01428973 - Minitransplants With HLA-matched Donors : Comparison Between 2 GVHD Prophylaxis Regimens Phase 2
Not yet recruiting NCT00749164 - Allogeneic Mesenchymal Stem Cell for Graft-Versus-Host Disease Treatment Phase 1/Phase 2
Completed NCT00993343 - Randomized Trial Comparing Sirolimus and Tacrolimus Versus Cyclosporine and Methotrexate as Graft-versus-host Disease (GVHD) Prophylaxis After Allogeneic Stem Cell Transplantation Phase 3
Completed NCT00360685 - Tacrolimus and Mycophenolate Mofetil (MMF) in GVHD Prophylactic Regimen Compared to Tacrolimus and Methotrexate (MTX N/A
Active, not recruiting NCT04503616 - Cyclophosphamide, Abatacept, and Tacrolimus for GvHD Prevention Phase 1/Phase 2
Terminated NCT02080195 - Nonmyeloablative Conditioning and Transplantation for Patients With Refractory Systemic Lupus Erythematosus (SLE) Phase 1/Phase 2
Completed NCT02193880 - Safety of Post-transplant Alpha-beta Depleted T-cell Infusion Following Haploidentical Stem Cell Transplant (Haplo SCT) N/A
Completed NCT02942173 - CD45RA Depleted T-cell Infusion for Prevention of Infections After TCRab/CD19-depleted Allo-HSCT Phase 2/Phase 3
Completed NCT02145403 - Phase 1/2 Study of Carfilzomib for the Prevention of Relapse and GVHD in Allo-HCT for Hematologic Malignancies Phase 1/Phase 2
Recruiting NCT01941394 - Mesenchymal Stem Cells Infusion for aGVHD Prophylaxis Transplantation Phase 2
Completed NCT00141713 - The Use of Etanercept (Enbrel®) in the Treatment of Acute Graft-Versus-Host Disease Phase 2
Recruiting NCT01991301 - Carfilzomib for the Prevention of Graft Versus Host Disease Phase 1
Completed NCT00408928 - Study on the Safety and Effectiveness of VELCADE® in the Treatment of Graft-Versus-Host Disease Phase 2
Completed NCT01633229 - Bone Marrow Stromal Cell Infusions for Stem Cell Transplant Complications Phase 1
Completed NCT05856058 - To Assess SHR0302 Oral Solutions and Tablets in Healthy Subjects Clinical Studies of Relative Bioavailability Phase 1
Completed NCT02342613 - Adoptive Immunotherapy With Activated Marrow Infiltrating Lymphocytes and Cyclophosphamide Graft-Versus-Host Disease Prophylaxis in Patients With Relapse of Hematologic Malignancies After Allogeneic Hematopoietic Cell Transplantation Phase 1
Recruiting NCT06423131 - Prospective Clinical Trial for Children With TCRαβ Depleted vs Traditional Haplo Identicle HSCT N/A
Completed NCT02144025 - Prevention of Ocular Graft-Versus-Host Disease With Topical Cyclosporine in Recipients of Allogeneic HSCT Phase 2
Completed NCT01369914 - The Natural History of Graft-Versus-Host Disease in the Eyes
Completed NCT00806728 - Study of MEDI-507 in With Steroid-Resistant Acute Graft-Versus-Host Disease Phase 1